Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Feb;28(2):87–92. doi: 10.1007/BF00199107

Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro

Khalid Ahmed 1,✉, John L Turk 1
PMCID: PMC11038598  PMID: 2783891

Abstract

Four anticancer agents, neothramycin, aclacinomycin, FK-565 and FK-156, were tested for their effects on concanavalin-A-induced interleukin-2 release from rat splenocytes in vitro. Neothramycin showed an enhancement of the release of interleukin-2, whereas aclacinomycin had no effect. FK-565 and FK-156 were found to inhibit the release of interleukin-2 under similar conditions. The inhibition was much more marked with FK-565. These drugs were also tested for their effects on the release of interleukin-1 from rat peritoneal exudate cells stimulated by lipopolysaccharide in vitro. Neothramycin and aclacinomycin did not affect the release of interleukin-1; however, both FK-565 and FK-156 resulted in its enhanced release under these conditions.

Keywords: Cancer Research, Similar Condition, Anticancer Agent, Peritoneal Exudate, Peritoneal Exudate Cell

References

  • 1.Abdul Hamied TA, Parker D, Turk JL. Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology. 1986;12:27. doi: 10.1016/0162-3109(86)90038-x. [DOI] [PubMed] [Google Scholar]
  • 2.Abdul Hamied TA, Parker D, Turk JL. Effects of adriamycin, 4-hydroperoxy cyclophosphamide and ASTA-Z (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol. 1987;9:355. doi: 10.1016/0192-0561(87)90061-0. [DOI] [PubMed] [Google Scholar]
  • 3.Abdul Hamied TA, Turk JL. Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo. Cancer Immunol Immunother. 1987;25:245. doi: 10.1007/BF00199154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ahmed K, Abdul Hamied TA, Turk JL. Inhibition of release of interleukin-2 by vincristine and vinblastine. Immunopharmacol Immunotoxicol. 1987;9:391. doi: 10.3109/08923978709035221. [DOI] [PubMed] [Google Scholar]
  • 5.Dickneite G, Kurrle R, Seiler FR, Sedlacek HH. Immunosuppression as a desired pharmacological effect. Behring Inst Mitt. 1984;74:250. [PubMed] [Google Scholar]
  • 6.Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1980;120:2027. [PubMed] [Google Scholar]
  • 7.Gotah T, Nakahara K, Nishiara T, Hashimoto M, Kino T, Kuroda Y, Okuhara M, Koshaka M, Aoki H, Imanaka H. Studies on a new immunoactive peptide FK-156, fermentation, extraction, and chemical and biological characterization. J Antibiot. 1982;35:1286. doi: 10.7164/antibiotics.35.1286. [DOI] [PubMed] [Google Scholar]
  • 8.Hamada M, Takeuchi T. New antitumour antibiotics, aclacinomycin A and B. J Antibiot. 1975;28:830. [Google Scholar]
  • 9.Hisamatsu T, Uchida S, Takeuchi T, Ishizuka M, Umezawa H. Antitumour effect of a new antibiotic neothramycin. Gann. 1980;71:308. [PubMed] [Google Scholar]
  • 10.Holtermann OA, Klein E, Casale GP. Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cell Immunol. 1973;9:339. doi: 10.1016/0008-8749(73)90049-x. [DOI] [PubMed] [Google Scholar]
  • 11.Ishizuka M, Takeuchi T, Masuda T, Fukasawa S, Umezawa H. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A. J Antibiot. 1981;34:331. doi: 10.7164/antibiotics.34.331. [DOI] [PubMed] [Google Scholar]
  • 12.Ishizuka M, Takeuchi T, Umezawa H. Immunomodulatory effects of antitumor antibiotics aclacinomycin, oxanisone, neothramycin and mazethramycin. Sapporo Cancer Semin Abstr. 1983;3:9. [Google Scholar]
  • 13.Izumi S, Nakahara K, Gotoh T, Hashimoto S, Kino T, Okuhara M, Aoki H, Imanaka H. Antitumor effects of novel immunoactive peptide FK-156 and its synthetic derivatives. J Antibiot. 1983;36:566. doi: 10.7164/antibiotics.36.566. [DOI] [PubMed] [Google Scholar]
  • 14.Kaye J, Porcelli S, Tite J, Jones B, Janeway CA. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen presenting cells in the activation of cells. J Exp Med. 1983;158:836. doi: 10.1084/jem.158.3.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Matsushima K, Kuang Y, Tosato G, Hopkins SJ, Oppenheim JJ. B cell derived interleukin 1 (IL-1) like factor I. Relationship of production of IL-1 like factor to accessory cell function of Epstein-Barr virus transformed human B lymphoblast cell lines. Cell Immunol. 1985;94:406. doi: 10.1016/0008-8749(85)90264-3. [DOI] [PubMed] [Google Scholar]
  • 16.Mihich E, Ehrke JM, Ishizuka M. Immunomodulation by antiobiotics. In: Mihich E, Sakurai Y, editors. Biological responses in cancer, vol 3. New York: Plenum Press; 1985. pp. 85–87. [Google Scholar]
  • 17.Mine Y, Watanabe Y, Tawara S, Yokota Y, Nishida M. Immunoactive peptides FK-156 and FK-565. Enhancement of host defence mechanisms against infection. J Antibiot. 1983;36:105918. doi: 10.7164/antibiotics.36.1059. [DOI] [PubMed] [Google Scholar]
  • 18.Oki T, Takeuchi T, Oka S, Umezawa H. New anthracycline antibiotic aclacinomycin A: experimental studies and correlation with clinical trials' recent results. Cancer Res. 1981;76:21. doi: 10.1007/978-3-642-81565-2_4. [DOI] [PubMed] [Google Scholar]
  • 19.Parker D, Turk JL. Potentiation of T lymphocyte function by bleomycin. Immunopharmacology. 1984;7:109. doi: 10.1016/0162-3109(84)90060-2. [DOI] [PubMed] [Google Scholar]
  • 20.Simpson E, Beverley PCL. Cell mediated responses to tumor xenografts in mice. Int J Cancer. 1972;9:299. doi: 10.1002/ijc.2910090207. [DOI] [PubMed] [Google Scholar]
  • 21.Takeuchi T, Umezawa H. Antitumor activity of new anthracycline antibiotic aclacinomycin A and its analogues, and their cytotoxicity. Gann. 1977;68:685. [PubMed] [Google Scholar]
  • 22.Takeuchi T, Miyamoto M, Ishizuka M, Naganawa H, Kondo S, Hamada M, Umezawa H. Neothramycin A and B, new antitumour antibiotics. J Antibiot. 1976;29:93. doi: 10.7164/antibiotics.29.93. [DOI] [PubMed] [Google Scholar]
  • 23.Thomson AW, Moon DK, Geczy CL, Nelson DS. Cyclosporin A inhibits lymphokine production but not the response of macrophages to lymphokines. Immunology. 1983;48:291. [PMC free article] [PubMed] [Google Scholar]
  • 24.Watanabe Y, Tawara S, Mine Y, Kikuchi H. Immunoactive peptides FK-156 and FK-565 — activation of mouse macrophages. J Antibiot. 1985;38:1781. doi: 10.7164/antibiotics.38.1781. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES